On 20 Nov 2025, Venus Remedies recorded an intraday peak of Rs.702, marking both a fresh 52-week and all-time high for the stock. This milestone reflects a notable phase of upward movement, with the stock outperforming its sector by 6.21% on the day. The stock opened with a gap up of 3.13%, signalling robust buying interest from the outset of trading.
Over the last two trading days, Venus Remedies has delivered a cumulative return of 23.31%, demonstrating a clear upward trajectory. The stock is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically indicates sustained positive momentum and investor confidence in the medium to long term.
Comparatively, the broader market benchmark, the Sensex, also recorded a new 52-week high today, trading at 85,296.64 points. The Sensex opened higher at 85,470.92 with a gain of 284.45 points (0.33%) but settled slightly lower during the session. Mega-cap stocks led the market gains, with the Sensex maintaining a position above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a bullish market environment.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Venus Remedies’ one-year performance stands out distinctly, with a return of 127.02%, significantly surpassing the Sensex’s 9.93% return over the same period. The stock’s 52-week low was Rs.272.20, highlighting the extent of the rally over the past year. This performance is supported by the company’s financial metrics, which show a net profit growth of 473.5% in the most recent quarter, with a quarterly PAT of Rs.20.13 crore.
The company’s return on capital employed (ROCE) for the half-year period reached 13.99%, while the inventory turnover ratio stood at 6.58 times, both indicating efficient utilisation of resources and operational effectiveness. Additionally, Venus Remedies maintains a low average debt-to-equity ratio of zero, reflecting a conservative capital structure.
Valuation metrics also present an attractive picture. The company’s return on equity (ROE) is 10.5%, and it trades at a price-to-book value of 1.5, which is considered fair relative to its peers and historical averages. The price-to-earnings-to-growth (PEG) ratio of 0.1 further suggests that the stock’s price is aligned with its earnings growth trajectory.
Thinking about Venus Remedies ? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Venus Remedies has reported positive results for four consecutive quarters, reinforcing the consistency in its financial performance. Over the past year, profits have risen by 183%, complementing the strong stock returns. The company’s market capitalisation grade is rated at 4, indicating a mid-sized presence within its sector.
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund participation may reflect a cautious stance or differing assessment of the stock’s valuation or business fundamentals.
In summary, Venus Remedies’ achievement of a new 52-week high at Rs.702 is supported by strong financial results, efficient operational metrics, and a favourable market environment. The stock’s performance over the past year has been markedly superior to the broader market, with sustained momentum evident in recent trading sessions.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
